Reviva Pharmaceuticals (RVPH) stock crashed over 40% in pre-market trading after pricing a $10 million public offering at a 20% discount. The funds will support the Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia. This drop follows the company's recent 1-for-20 reverse share split, pushing shares toward record lows.